Creative Medical Technology Holdings (NASDAQ: CELZ) announced that its BioDefense Inc. Burn Pit Initiative has received regulatory approval to proceed, marking a key milestone in…
January 06, 2026
January 06, 2026
AI-Driven ERP Agents: New Competitive Edge for Pharma
Pharmaceutical companies are increasingly exploring artificial intelligence (AI) agents integrated with Enterprise Resource Planning (ERP) systems to automate routine business processes — from supplier communications…
January 05, 2026
MapLight Therapeutics’ ML-007C/MA Earns FDA Fast Track Designation for Alzheimer’s Disease Psychosis
MapLight Therapeutics (Nasdaq: MPLT) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational therapy ML-007C/MA for the…
The U.S. Food and Drug Administration (FDA) has approved the first at-home brain-stimulation device for the treatment of major depressive disorder (MDD), marking an important…
December 29, 2025
Sellas Life Sciences Updates Pivotal Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
Sellas Life Sciences Group, Inc. (NASDAQ: SLS) provided a progress update on its ongoing pivotal Phase 3 REGAL clinical trial evaluating galinpepimut-S (GPS) in patients…
Gilead Sciences (NASDAQ: GILD) has agreed to acquire RP-3467, an investigational cancer therapy developed by Repare Therapeutics (NASDAQ: RPTX), in a transaction valued at up…
December 17, 2025
Biotech Shows Signs of Recovery as Innovation, M&A, and AI Set the Stage for a New Growth Cycle
After several challenging years marked by regulatory uncertainty, rising interest rates, and risk-off investor sentiment, the biotechnology sector is showing growing signs of recovery. Improving…
Cencora (NYSE: COR) is moving forward with plans to acquire majority control of OneOncology, a U.S.-based oncology care network, in a transaction that values the…
December 17, 2025
Oncolytics Biotech Reports Encouraging Data for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released new clinical and translational data supporting the potential of its lead immunotherapy candidate, pelareorep, in second-line metastatic colorectal…
December 10, 2025
MAIA Targets Large Immunotherapy Opportunity with Novel Telomere-Focused Cancer Approach
MAIA Biotechnology (NYSE American: MAIA) outlined its strategy to address a significant unmet need in oncology through its lead asset, atevagenosine (THIO), a differentiated cancer…
December 03, 2025
CollPlant Biotechnologies (CLGN): PRISM MarketView’s New Emerging Index Sector Addition
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN), a pioneering company in regenerative and aesthetic medicine, continues to strengthen its position in the biotech landscape and was recently…
November 13, 2025
Day One Biopharmaceuticals Acquires Mersana Therapeutics to Bolster Oncology Pipeline
Day One Biopharmaceuticals (NASDAQ: DAWN) has entered into a definitive agreement to acquire Mersana Therapeutics, (NASDAQ: MRSN) a clinical-stage biotech known for its antibody-drug conjugate…